High Prevalence of Cannabinoid Receptor 1 Expression in Thai Patients with Cholangiocarcinoma and Its Prognostic Implications.

Q2 Medicine

Asian Pacific Journal of Cancer Prevention Pub Date : 2026-09-01 DOI:10.31557/APJCP.2026.27.9.3349

Teerapat Ungtrakul, Chitiarpa Amatawet, Thaniya Sricharunrat

{"title":"High Prevalence of Cannabinoid Receptor 1 Expression in Thai Patients with Cholangiocarcinoma and Its Prognostic Implications.","authors":"Teerapat Ungtrakul, Chitiarpa Amatawet, Thaniya Sricharunrat","doi":"10.31557/APJCP.2026.27.9.3349","DOIUrl":null,"url":null,"abstract":"Objective: Cholangiocarcinoma (CCA) is highly prevalent in Thailand and remains associated with poor outcomes. Emerging evidence suggests that dysregulation of the endocannabinoid system may be involved in CCA pathogenesis and prognosis. This study aimed to evaluate the prevalence of cannabinoid receptor 1 (CB1) expression and its association with clinicopathological features and survival outcomes in Thai patients with CCA.Methods: We retrospectively reviewed patients with histologically confirmed CCA treated at a tertiary cancer center in Thailand between January 2014 and December 2018. CB1 expression in tumor tissues was assessed by immunohistochemistry and semi-quantitatively scored according to staining intensity and extent.Results: Tumor specimens from 51 patients (median age 59 years; 41% female) were analyzed. Most patients had intrahepatic CCA (80%), and 47% presented with advanced-stage disease (stages III-IV). High CB1 expression was observed in 46 of 51 cases (90%). Patients with high CB1 expression more frequently had advanced-stage disease. During a median follow-up of 27.8 months, 34 patients died. The median overall survival (OS) was 18.5 months (95% CI, 6.1-36.5). There was no statistically significant difference in OS between patients with high and low CB1 expression (median OS 18.5 vs. 23.0 months, respectively; p = 0.68).Conclusion: High CB1 expression is highly prevalent in Thai patients with CCA. While no significant associations with clinicopathological features or survival were found in this small cohort, the widespread overexpression of CB1 supports its potential biological and therapeutic relevance in CCA and warrants further investigation in larger studies.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3349-3354"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2026.27.9.3349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Cholangiocarcinoma (CCA) is highly prevalent in Thailand and remains associated with poor outcomes. Emerging evidence suggests that dysregulation of the endocannabinoid system may be involved in CCA pathogenesis and prognosis. This study aimed to evaluate the prevalence of cannabinoid receptor 1 (CB1) expression and its association with clinicopathological features and survival outcomes in Thai patients with CCA.

Methods: We retrospectively reviewed patients with histologically confirmed CCA treated at a tertiary cancer center in Thailand between January 2014 and December 2018. CB1 expression in tumor tissues was assessed by immunohistochemistry and semi-quantitatively scored according to staining intensity and extent.

Results: Tumor specimens from 51 patients (median age 59 years; 41% female) were analyzed. Most patients had intrahepatic CCA (80%), and 47% presented with advanced-stage disease (stages III-IV). High CB1 expression was observed in 46 of 51 cases (90%). Patients with high CB1 expression more frequently had advanced-stage disease. During a median follow-up of 27.8 months, 34 patients died. The median overall survival (OS) was 18.5 months (95% CI, 6.1-36.5). There was no statistically significant difference in OS between patients with high and low CB1 expression (median OS 18.5 vs. 23.0 months, respectively; p = 0.68).

Conclusion: High CB1 expression is highly prevalent in Thai patients with CCA. While no significant associations with clinicopathological features or survival were found in this small cohort, the widespread overexpression of CB1 supports its potential biological and therapeutic relevance in CCA and warrants further investigation in larger studies.

查看原文本刊更多论文

大麻素受体1在泰国胆管癌患者中的高表达及其预后意义

目的：胆管癌（CCA）在泰国非常普遍，并且仍然与不良预后相关。新出现的证据表明，内源性大麻素系统的失调可能参与了CCA的发病机制和预后。本研究旨在评估泰国CCA患者中大麻素受体1 （CB1）表达的患病率及其与临床病理特征和生存结局的关系。方法：我们回顾性分析了2014年1月至2018年12月在泰国一家三级癌症中心接受组织学证实的CCA治疗的患者。采用免疫组化方法检测CB1在肿瘤组织中的表达，并根据染色强度和程度进行半定量评分。结果：分析了51例患者的肿瘤标本（中位年龄59岁，41%为女性）。大多数患者有肝内CCA(80%)， 47%出现晚期疾病（III-IV期）。51例患者中46例（90%）CB1高表达。CB1高表达的患者更容易出现晚期疾病。在27.8个月的中位随访期间，34名患者死亡。中位总生存期（OS）为18.5个月（95% CI, 6.1-36.5）。CB1高、低表达患者的OS差异无统计学意义（中位OS分别为18.5个月和23.0个月，p = 0.68）。结论：CB1高表达在泰国CCA患者中非常普遍。虽然在这个小队列中没有发现与临床病理特征或生存率的显著关联，但CB1的广泛过表达支持其在CCA中的潜在生物学和治疗相关性，值得在更大规模的研究中进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.